Stockreport

Neurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program [Yahoo! Finance]

Neurogene Inc.  (NGNE) 
PDF START Program provides sponsors enhanced communications with FDA to accelerate development of rare disease therapies NEW YORK, June 03, 2024 BUSINESS WIRE )--Neurogen [Read more]